Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions

JOSÉ LUIS FERNÁNDEZ-SUEIRO
The Journal of Rheumatology April 2012, 39 (4) 677-678; DOI: https://doi.org/10.3899/jrheum.120095
JOSÉ LUIS FERNÁNDEZ-SUEIRO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: L.sueiro@canalejo.org
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Psoriatic arthritis (PsA) is a complex disease characterized by the presence of polyarthritis, spinal disease, dactylitis, enthesitis, and cutaneous involvement1. Due to considerable research efforts in PsA in recent years, criteria for classification of PsA2 (the CASPAR criteria) have been developed, as well as definitions of clinical features and how to assess them3. In terms of evaluating disease activity, efforts are being made to determine whether composite measures of disease activity and response to therapy can be developed to cover all the domains that characterize PsA4.

At present a patient can be classified as having PsA by meeting the CASPAR criteria; nevertheless, in applying the criteria, it is mandatory that the patient must have an inflammatory articular disease (joint, spine, or entheseal). The lack of definition of these entry criteria, crucial for applying the CASPAR criteria, may explain some of the difficulties in clinical research in PsA; for instance, validation of the CASPAR criteria for diagnostic purposes encounters difficulty when criteria are used in a general setting5.

Two recent studies5,6 testing the sensitivity of the CASPAR criteria in early PsA found different results (99.1% vs 77.3%); apart from the methodological differences in the 2 studies, it is important to emphasize that the clinical diagnosis of PsA relied on clinical expertise as the “gold standard.” Moreover, as many as 43% of patients, in the study with the lowest sensitivity, had a clinical pattern of tenosynovitis, enthesitis, or dactylitis. When tested against noninflammatory diseases7 (osteoarthritis and fibromyalgia, FM), in established PsA the sensitivity was 96.1% and the specificity 87.5%.

Recent evidence shows a great divergence between clinical and image findings (total body scintigraphy and ultrasound, US) in early PsA8, such that subclinical disease was demonstrated and the pattern of arthritis was reclassified. Again in the same study, clinical diagnosis was the gold standard and as many as three-quarters of patients had oligoenthesoarthritis.

The presence of “occult” or “painless” disease9 is another important issue when considering a clinical diagnosis of PsA. Several studies have demonstrated, especially in spinal disease10, the presence of disease without symptoms. Studies using new imaging techniques such as magnetic resonance imaging (MRI) and high-resolution US found subclinical signs of arthritis11 or lower limb entheseal abnormalities12 in patients with psoriasis. A high prevalence (∼70%) of entheseal abnormalities was also found in patients with PsA using power Doppler US (PDUS)13,14.

The lack of a definition of inflammatory articular disease and the recent findings with the newer imaging techniques create problems with the diagnosis of PsA, especially when the spine and enthesis are involved15.

Enthesitis is considered a major feature of PsA and can sometimes be the sole manifestation of early PsA8,16, yet the clinical diagnosis of enthesitis may be difficult. Enthesitis is widely acknowledged as a domain that must be included in the assessment of disease activity in PsA3,4; however, clinical exploration, based on the presence or absence of pain by applying enough pressure to blanch the tip of the finger, is equivocal. FM is a condition17 characterized by the presence of widespread pain associated with at least 11 of 18 tender points sites on digital palpation; its prevalence in the general population varies between 2% and 4%, and in some cases is associated with rheumatic diseases. The presence of FM in a rheumatic disease can confuse accurate evaluation of disease18.

Given that enthesitis and FM are characterized by the presence of tender points, it is relevant to be able to distinguish both conditions in a patient with cutaneous psoriasis; using current CASPAR criteria (without a definition of enthesitis) there is a probability of misclassifying some of these patients.

In this issue of The Journal Marchesoni and colleagues19 report the clinical features that can help a physician on clinical grounds to differentiate PsA from FM. A patient has the highest probability of having FM if ≥ 6 somatic manifestations (according to the new diagnostic criteria for FM) and ≥ 8 tender points are present; thus, if a patient has both criteria, a diagnosis of primary or secondary FM can be made.

Their study, however, raises many questions: the Maastricht Ankylosing Spondylitis Enthesitis Index (MASES), used for measuring enthesitis, showed overlap between the 2 diseases. On the other hand, recent work with PDUS has shown a high prevalence of entheseal abnormalities (∼70%) in patients with PsA and a poor correlation between PDUS and MASES14,15. These data emphasize the difficulties in assessing and understanding the clinical relevance of “at least” some entheseal involvement in PsA.

Studies with US and PDUS have demonstrated a high prevalence of entheseal abnormalities in patients with psoriasis without PsA12,20; these findings raise the question of their specificity and clinical meaning. If the lesions found were considered to be specific, many of these patients could be classified as entheseal PsA and would therefore meet the CASPAR criteria.

There is thus a need to clarify several questions concerning entheseal involvement in PsA: (1) to find an accepted and agreed-on method of clinical exploration; (2) to develop a reliable definition of enthesopathy using PDUS, in other words, based on active lesions; (3) to establish correlations between clinical and PDUS findings; (4) to determine the clinical relevance of PDUS findings, not only in psoriasis patients without arthritis, but also in patients with PsA; and (5) to explore the utility of MRI in assessing the entheseal involvement in PsA.

When all these issues have been resolved, a clear definition of entheseal involvement may emerge, and clinicians will be more confident about making decisions, whether for the purpose of diagnosis or for indicating clinical treatments based on objective findings.

Footnotes

  • Supported by a grant from the Fondo de Investigaciones Sanitarias, FIS 08/0789, Ministry of Health, Spain.

REFERENCES

  1. 1.↵
    1. Gladman D,
    2. Antoni C,
    3. Mease P,
    4. Clegg D,
    5. Nash P
    . Psoriatic arthritis: Epidemiology, clinical features, course and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14–17.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H; and
    7. the CASPAR study group
    . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mease P
    . Measures of psoriatic arthritis. Arthritis Care Res 2011;63 Suppl 11:S64–S85.
    OpenUrlCrossRef
  4. 4.↵
    1. Mumtaz A,
    2. Gallagher P,
    3. Kirby B,
    4. Waxman R,
    5. Coates L,
    6. Veale D,
    7. et al.
    Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Chandran V,
    2. Schentag C,
    3. Gladman D
    . Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007;57:1560–3.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. D’Angelo S,
    2. Mennillo G,
    3. Cutro M,
    4. Leccese P,
    5. Nigro A,
    6. Padula A
    . Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. J Rheumatol 2009;36:368–70.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Fernández-Sueiro JL,
    2. González Diaz de Rábago E,
    3. Fernández Lopez JC,
    4. Oreiro Villar N,
    5. Pinto Tasende,
    6. Lema Gontad JM,
    7. et al.
    Validation of CASPAR criteria in a Spanish population: Comparison with potential confounding inflammatory diseases [abstract]. Ann Rheum Dis 2010;69 Suppl 3:699.
    OpenUrl
  8. 8.↵
    1. Scarpa R,
    2. Cuocolo A,
    3. Peluso R,
    4. Atteno M,
    5. Gisonni P,
    6. Iervolino S,
    7. et al.
    Early psoriatic arthritis: The clinical spectrum. J Rheumatol 2008;35:137–41.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Palazzi C,
    2. Lubrano E,
    3. D’Angelo S,
    4. Olivieri I
    . Beyond early diagnosis: Occult psoriatic arthritis. J Rheumatol 2010;37:1556–8.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Queiro R,
    2. Belzunegui J,
    3. Gonzalez C,
    4. De Dios J,
    5. Sarasqueta C,
    6. Torre J,
    7. et al.
    Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Clin Rheumatol 2002;21:10–3.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Offidani A,
    2. Cellini A,
    3. Valeri G,
    4. Giovagnoni A
    . Subclinical joint involvement in psoriasis: Magnetic resonance imaging and x-rays findings. Acta Dermatol Venereol 1998;58:2248–56.
    OpenUrl
  12. 12.↵
    1. Gisondi P,
    2. Tinazzi I,
    3. El-Dalati G,
    4. Gallo M,
    5. Biasi D,
    6. Barbar L
    . Lower limb enthesopathy in patients with psoriasis without clinical sings of arthropathy: A hospital-based case control study. Ann Rheum Dis 2008;67:26–30.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Fernández Sueiro JL,
    2. Pinto Tasende JA,
    3. González Diaz de Rábago E,
    4. Pértega S,
    5. Fernández Lopez JC,
    6. et al.
    Prevalence of enthesitis and concordance of enthesitis exploration with ultrasound versus clinical exploration in psoriatic arthritis [abstract]. Ann Rheum Dis 2010;69:580.
    OpenUrl
  14. 14.↵
    1. Iagnocco A,
    2. Spadaro A,
    3. Marchesoni A,
    4. Cauli A,
    5. De Lucia O,
    6. Gabba A,
    7. et al.
    Power Doppler ultrasonographic evaluation of enthesitis in psoriatic arthritis. A multi-center study. Joint Bone Spine 2011 Nov 25. [Epub ahead of print]
  15. 15.↵
    1. Fernandez-Sueiro JL
    . The challenge and the need of defining axial psoriatic arthritis. J Rheumatol 2009;36:2633–4.
    OpenUrlFREE Full Text
  16. 16.↵
    1. Godfrin B,
    2. Zabraniecki L,
    3. Lamboley V,
    4. Bertrand-Latour F,
    5. Sans N,
    6. Fournié B
    . Spondyloarthropathy with entheseal pain. A prospective study in 33 patients. Joint Bone Spine 2004;71:557–62.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Wolfe F,
    2. Smythe HA,
    3. Yunus MB,
    4. Bennett RM,
    5. Bombardier C,
    6. Goldenberg DL,
    7. et al.
    The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160–72.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Almodovar R,
    2. Carmona L,
    3. Zarco P,
    4. Collantes E,
    5. González C,
    6. Mulero J,
    7. et al.
    Fibromyalgia in patients with ankylosing spondylitis: Prevalence and utility of the measures of activity, function and radiologic damage. Clin Exp Rheumatol 2010;28:S33–S39.
    OpenUrlPubMed
  19. 19.↵
    1. Marchesoni A,
    2. Atzeni F,
    3. Spadaro A,
    4. Lubrano E,
    5. Provenzano G,
    6. Cauli A,
    7. et al.
    Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 2012;39:849–55.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Naredo E,
    2. Möller I,
    3. de Miguel E,
    4. Batlle-Gualda E,
    5. Acebes C,
    6. Brito E,
    7. et al.
    High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without arthritis: A prospective case-control study. Rheumatology 2011;50:1838–48.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 4
1 Apr 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions
JOSÉ LUIS FERNÁNDEZ-SUEIRO
The Journal of Rheumatology Apr 2012, 39 (4) 677-678; DOI: 10.3899/jrheum.120095

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions
JOSÉ LUIS FERNÁNDEZ-SUEIRO
The Journal of Rheumatology Apr 2012, 39 (4) 677-678; DOI: 10.3899/jrheum.120095
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Sex Effect in Psoriatic Arthritis
  • Microdissecting Epigenetic Pathways in Oligoarticular Juvenile Idiopathic Arthritis: A New Avenue in Transforming Growth Factor β?
  • Ro52, Myositis, and Interstitial Lung Disease
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire